Year None202320222021202020192018201720162015201420132012 02.16.2023 Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy 02.02.2023 Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 01.04.2023 Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 01.03.2023 Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors 12.20.2022 Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy 12.02.2022 Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11.30.2022 Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock 11.30.2022 Iveric Bio Announces Proposed Offering of Common Stock 11.17.2022 Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy 11.04.2022 Iveric Bio to Present at Upcoming Investor Conferences Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
